الفهرس 
Formulation of controlled release dosage forms of a short half life anti-inflammatory drug
AbstractOnly 14 pages are availabe for public view
 |  | from | 293 |  |  |
| | | from | 293 | | |
Abstract
The aim of this study is to formulate a once-daily sustained release oral formulation of the frequently administered and the highly soluble drug, Dexketoprofen trometamol (DT), which can reduce the frequency of administration, adverse effects and improve patient compliance. Chapter 1 included the preparation of twenty five sustained released dexketoprofen trometamol microspheres (DTM) using the emulsification solvent evaporation technique, adopting the D-optimal design. In chapter 2, combined release retardant multiple-unit systems (CRRMUS) were prepared by combining an immediate release mini-tablets and an ileo-cecal release retardant mini-matrix tablets, together with the previously prepared optimized microsphere formula either in tablet (CRRMUS tablets), in capsules (CRRMUS capsules) or in enteric coated capsule inside a hard gelatin capsule (CRRMUSECC capsules) to achieve the required linear sustained release profile for extended delivery of DT for once daily administration. Chapter 3 involved the preparation of release retardant mini-matrix tablets (RRMMT) using hydrophilic time dependent polymers which were used for targeting and sustaining the release of DT at the duodeno-jejunal and ileo-cecal regions of the GIT. The different site-specific RRMMT were combined into single solid dosage form (tablet or capsule), namely, combined site specific release retardant mini-matrix (CSSRRMM) tablets and CSSRRMM capsules, respectively, to achieve the required linear sustained release profile for extended delivery of DT for once daily administration